Shannonside Region: State Invests Nearly €2.63 Million on Ozempic

New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.

New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year.

Longford and Westmeath had the highest expenses, totaling about €1.4 million.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Roscommon recorded spending of just under €548,000, while Sligo and Leitrim recorded just over €685,000. Nationally, the total expenditure is close to €40 million.

These figures encompass prescriptions for patients receiving general medical services and those with long-term illnesses. Health tracking apps like Shotlee can help monitor medication adherence.

Source Information

Originally published by Shannonside.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds

A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.

7 min read

Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read

Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read

Same topic: Healthcare

All Healthcare articles →

Finance

Should You Invest in Novo Nordisk, the Ozempic Manufacturer, in 2026?

Investing in Novo Nordisk (NVO), the maker of Ozempic and Wegovy, has faced challenges recently, with shares declining. However, recent FDA approval of an oral form of Wegovy could change the company's trajectory. Analyzing competition and market dynamics is vital for investment decisions.

2 min read

Finance

Semaglutide to Potentially Boost Ajanta Pharma's Growth Trajectory | Stock Market Update

Ajanta Pharma's recent agreement to market semaglutide across emerging markets has the potential to influence its medium-term growth. The company's established presence and strategic focus on branded generics contribute to a positive outlook. Financial analysts predict substantial revenue increases in the coming years.

3 min read

Health

Uzbekistan Approves Initial Local Version of Danish Obesity Medication Ozempic

Uzbekistan has registered Semavik, a Russian-produced medication containing semaglutide, designed to treat type 2 diabetes and obesity. This marks the first local equivalent of the Danish drug Ozempic in the country. The approval addresses the increasing prevalence of metabolic diseases.

1 min read

More in Health

Health & Wellness

Ozempic and the Shift: Real Data on America's Obesity Rates

New data from EPIC Research highlights a correlation between rising GLP-1 prescriptions and a modest decline in US obesity rates, offering hope amidst ongoing challenges.

7 min read

Health & Wellness

Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?

New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.

7 min read

Health & Wellness

Beyond the Headlines: Navigating Severe GLP-1 Side Effects

Actress Mayim Bialik's recent experience with severe gastrointestinal distress after starting a GLP-1 medication has brought a critical conversation to the forefront: the reality of significant side effects associated with these popular drugs. While GLP-1s offer profound benefits for many, understanding and managing potential adverse reactions is paramount.

7 min read